Pharmacokinetics and tissue distribution in rats of a novel anticancer platinum compound LLC-1903

References

• Apostoli P. (2002). Element in environmental and occupational medicine. J Chromatogr B 778:63–97.
   PubMed Web of Science ®Google Scholar
• Aris SM, Farrell NP. (2009). Towards antitumor active trans-platinum compounds. Eur J Inorg Chem 2009:1293–302.
   PubMedGoogle Scholar
• Awuah SG, Zheng YR, Bruno PM, et al. (2015). A platinum(IV) pro-drug preferentially targets IDO providing enhanced ovarian cancer immuno-chemotherapy. J Am Chem Soc 137:14854–7.
   PubMed Web of Science ®Google Scholar
• Bowler BE, Lippard SJ. (1986). Modulation of platinum antitumor drug binding to DNA by linked and free intercalators. Biochemistry 25:3031–8.
   PubMed Web of Science ®Google Scholar
• Buss I, Garmann D, Galanski M, et al. (2011). Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes. Eur J Inorg Chem 105:709–17.
   Google Scholar
• Cabral H, Nishiyama N, Kataoka K. (2007). Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity. J Control Release 121:146–55.
   PubMed Web of Science ®Google Scholar
• Chen HHW, Chen WC, Liang ZD, et al. (2015). Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy. Expert Opin Ther Tar 19:1307–17.
   PubMed Web of Science ®Google Scholar
• Cleare MJ, Hoeschele JD. (1973). Studies on the antitumor activity of group VIII transition metal complexes. Part I. Platinum (II) complexes. Bioinorg Chem 2:187–210.
   Google Scholar
• Coleman MD. (2005). Human drug metabolism. New Jersey: John Wiley & Sons, Ltd.
   Google Scholar
• Desoize B, Madoulet C. (2002). Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol 42:317–25.
   PubMed Web of Science ®Google Scholar
• Dilruba S, Kalayda GV. (2016). Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol 77:1103–24.
   PubMed Web of Science ®Google Scholar
• Dugbartey GJ, Peppone LJ, Graaf I. (2016). An integrative view of cisplatin-induced renal and cardiac toxicities: molecular mechanisms, current treatment challenges and potential protective measures. Toxicology 371:58–66.
   PubMed Web of Science ®Google Scholar
• Ehrsson H, Wallin I. (2003). Liquid chromatographic determination of oxaliplatin in blood using post-column derivatization in a microwave field followed by photometric detection. J Chromatogr B 795:291–4.
   PubMed Web of Science ®Google Scholar
• Engel JB, Martens T, Hahne JC, et al. (2012). Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro. Anticancer Drugs 23:426–36.
   PubMed Web of Science ®Google Scholar
• Gao AL, Yang Z, Yang XY, et al. (2017). Explanation of 1H NMR spectra of LLC-1903, a new anticancer lobaplatin derivative. Precious Metal 38:11–4.
   Google Scholar
• Goodisman J, Hagrman D, Tacka KA, et al. (2006). Analysis of cytotoxicities of platinum compounds. Cancer Chemoth Pharm 57:257–67.
   PubMed Web of Science ®Google Scholar
• Graham MA, Lockwood GF, Greenslade D, et al. (2000). Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6:1205–18.
   PubMed Web of Science ®Google Scholar
• Guchelaar HJ, Uges DRA, Aulenbacher P, et al. (1992). Stability of the new anticancer platinum analogue 1,2-diaminomethyl-cyclobutane-platinum(II)-lactate (Lobaplatin; D19466) in intravenous solutions. Pharm Res DORDR 09:808–11.
   Google Scholar
• Guo P, Li SL, Gallo JM. (2003). Determination of carboplatin in plasma and tumor by high-performance liquid chromatography–mass spectrometry. J Chromatogr B 783:43–52.
   PubMed Web of Science ®Google Scholar
• Hann S, Stefánka Z, Lenz K, et al. (2005). Novel separation method for highly sensitive speciation of cancerostatic platinum compounds by HPLC-ICP-MS. Anal Bioanal Chem 381:405–12.
   PubMed Web of Science ®Google Scholar
• Hassan I, Chibber S, Naseem I. (2013). Vitamin B2: a promising adjuvant in cisplatin based chemoradiotherapy by cellular redox management. Food Chem Toxicol 59:715–23.
   PubMed Web of Science ®Google Scholar
• He D, Yin S, Han F, et al. (2016). Pharmacokinetics and tissue distribution of two novel isomerism anticancer platinum compounds. Drug Dev Ind Pharm 42:1792–9.
   PubMed Web of Science ®Google Scholar
• Ho Y-P, Au-Yeung SCF, To KKW. (2003). Platinum-based anticancer agents: innovative design strategies and biological perspectives. Med Res Rev 23:633–55.
   PubMed Web of Science ®Google Scholar
• Hosey CM, Chan R, Benet LZ. (2016). BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs. AAPS J 18:251–60.
   PubMed Web of Science ®Google Scholar
• Iseri S, Ercan F, Gedik N. (2007). Simvastatin attenuates cisplatin-induced kidney and liver damage in rats. Toxicology 230:256–64.
   PubMed Web of Science ®Google Scholar
• Jelínková I, Šafaříková B, Blanářová OV, et al. (2014). Platinum(IV) complex LA-12 exerts higher ability than cisplatin to enhance TRAIL-induced cancer cell apoptosis via stimulation of mitochondrial pathway. Biochem Pharmacol 92:415–24.
   PubMed Web of Science ®Google Scholar
• Jungwirth U, Xanthos DN, Gojo J, et al. (2012). Anticancer activity of methyl-substituted oxaliplatin analogs. Mol Pharmacol 81:719–28.
   PubMed Web of Science ®Google Scholar
• Kasparkova J, Kostrhunova H, Novakova O, et al. (2015). A photoactivatable platinum(IV) complex targeting genomic DNA and histone deacetylases. Angew Chem 54:14478–82.
   Google Scholar
• Kelland L. (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573–84.
   PubMed Web of Science ®Google Scholar
• Khuhawar MY, Arain GM. (2005). Liquid chromatographic determination of cis-platin as platinum(II) in pharmaceutical preparation, serum and urine samples of cancer patients. Talanta 66:34–9.
   PubMed Web of Science ®Google Scholar
• Li H, Gao X, Liu R, et al. (2015). Glucose conjugated platinum(II) complex: antitumor superiority to oxaliplatin, combination effect and mechanism of action. Eur J Med Chem 101:400–8.
   PubMed Web of Science ®Google Scholar
• Liu QF, Li X, Su Q, et al. (2009). Investigation on pharmacokinetics, tissue distribution and excretion of a novel anticancer platinum compound by inductively coupled plasma mass spectrometry after intravenous administration to rats. Arch Pharm Res 32:1621–8.
   PubMed Web of Science ®Google Scholar
• Liu WP, Lou GL, Cheng XZ, et al. (2013). A kind of soluble and stable derivative of lobaplatin. China Patent 201310673678.1, 12, 12.
   Google Scholar
• Liu WP, Lou GL, Hou SQ, et al. (2014). A series of antitumor platinum(II) complexes of 3-oxo-cyclobutane-1, 1-dicarboxylate: China Patent CN 201410226135.X[P]. 2014-05-26.
   Google Scholar
• Loehrer PJ, Einhorn LH. (1984). Drugs five years later. cisplatin. Ann Intern Med 100:704–13.
   PubMed Web of Science ®Google Scholar
• Ma ESF, Bates WD, Edmunds A, et al. (2005). Enhancement of aqueous solubility and stability employing a trans acetate axis in trans planar amine platinum compounds while maintaining the biological profile. J Med Chem 48:5651–6554.
   PubMed Web of Science ®Google Scholar
• Margiotta N, Denora N, Ostuni R, et al. (2010). Platinum(II) complexes with bioactive carrier ligands having high affinity for the translocator protein. J Med Chem 53:5144–55.
   PubMed Web of Science ®Google Scholar
• Marzano C, Mazzega SS, Gandin V, et al. (2010). A new class of antitumor trans-amine-amidine-Pt(II) cationic complexes: influence of chemical structure and solvent on in vitro and in vivo tumor cell proliferation. J Med Chem 53:6210–27.
   PubMed Web of Science ®Google Scholar
• Meng XJ, Yang B, Gao JY, et al. (2015). Simultaneous quantitation of two diastereoisomers of lobaplatin in rat plasma by supercritical fluid chromatography with tandem mass spectrometry and its application to a pharmacokinetic study. J. Sep Sci 38:3803–9.
   PubMed Web of Science ®Google Scholar
• Montero EI, Díaz S, González-Vadillo AM, et al. (1999). Preparation and characterization of novel trans-[PtCl2(amine)(isopropylamine)] compounds: cytotoxic activity and apoptosis induction in ras-transformed cells. J Med Chem 42:4264–8.
   PubMed Web of Science ®Google Scholar
• Navarro M, Castro W, Higuera-Padilla AR, et al. (2011). Synthesis, characterization and biological activity of trans-platinum(II) complexes with chloroquine. J Inorg Biochem 105:1684–91.
   PubMed Web of Science ®Google Scholar
• Navolotskii DV, Ivanenko NB, Solovyev ND, et al. (2015). Pharmacokinetics and tissue distribution of novel platinum containing anticancer agent BP-C1 studied in rabbits using sector field inductively coupled plasma mass spectrometry. Drug Test Anal 7:737–44.
   PubMed Web of Science ®Google Scholar
• Raghavan R, Burchett M, Loffredo D, Mulligan JA. (2000). Low-level (PPB) determination of cisplatin in cleaning validation (rinse water) samples. I. An atomic absorption spectrophotometric method. Drug Dev Ind Pharm 26:429–40.
   PubMed Web of Science ®Google Scholar
• Saha P, Descôteaux C, Brasseur K, et al. (2012). Synthesis, antiproliferative activity and estrogen receptor α affinity of novel estradiol-linked platinum(II) complex analogs to carboplatin and oxaliplatin. Potential vector complexes to target estrogen-dependent tissues. Eur J Med Chem 48:385–90.
   PubMed Web of Science ®Google Scholar
• Shen W, Luan J, Cao L, et al. (2015). Thermogelling polymer–platinum(IV) conjugates for long-term delivery of cisplatin. Biomacromolecules 16:105–15.
   PubMed Web of Science ®Google Scholar
• Stewart DJ. (2007). Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hemat 63:12–31.
   PubMed Web of Science ®Google Scholar
• Su Q, Liu Q, Luo G, et al. (2008). Pharmacokinetic investigation on a novel antitumour platinum compound in rabbit plasma by inductively coupled plasma mass spectrometry after intravenous administration. Drug Dev Ind Pharm 34:472–7.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. (2010). Passive and active drug targeting: drug delivery to tumors as an example. Handbook Exper Pharmacol 197:3–53.
   PubMedGoogle Scholar
• Wang X, Guo Z. (2013). ChemInform abstract: targeting and delivery of platinum-based anticancer drugs. Chem Soc Rev 44:202–24.
   Google Scholar
• Welink J, Pechstein B, van der Vigh WJF. (1996). Determination of the two diastereoisomers of lobaplatin (D-19466) in plasma ultrafiltrate of cancer patients with a normal or an impaired kidney or liver function by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 675:107–11.
   PubMed Web of Science ®Google Scholar
• Wexselblatt E, Dan G. (2012). What do we know about the reduction of Pt(IV) pro-drugs. J Inorg Biochem 117:220–9.
   PubMed Web of Science ®Google Scholar
• Wheate NJ, Walker S, Craig GE, Oun R. (2010). The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton T 39:8113–27.
   PubMed Web of Science ®Google Scholar
• Yousef MI, Saad AA, El-Shennawy LK. (2009). Protective effect of grape seed proanthocyanidin extract against oxidative stress induced by cisplatin in rats. Food Chem Toxicol 47:1176–83.
   PubMed Web of Science ®Google Scholar
• Zhang J-S, Imai T, Suenaga A, Otagiri M. (2002). Molecular-weight-dependent pharmacokinetics and cytotoxic properties of cisplatin complexes prepared with chondroitin sulfate A and C. Inter J Pharmac 240:23–31.
   PubMed Web of Science ®Google Scholar
• Zhuo H, Timerbaev AR, Keppler BK. (2006). Determination of cisplatin and its hydrolytic metabolite in human serum by capillary electrophoresis techniques. J Chromatogr A 1106:75–9.
   PubMed Web of Science ®Google Scholar